Abstract:Organic chromium is of great interest and has become an important chromium supplement resource in recent years because of its low toxicity and easy absorption. In our previous study, we synthesized a novel organic chromium [GLP-Cr] through the chelation of Ganoderma lucidum polysaccharide and chromium (III). The purpose of this study was to investigate the beneficial effects of GLP-Cr on the improvement of metabolic syndromes (MetS) in mice fed with a high-fat and high-fructose diet (HFHFD) and its mechanism of action. The results indicated that oral administration of GLP-Cr inhibited the excessive exaltation of body weight, glucose tolerance, fasting blood glucose and lipid levels, hepatic total cholesterol (TC), triglyceride (TG) levels caused by HFHFD. Besides, 16S rRNA amplicon sequencing showed that GLP-Cr intervention evidently ameliorated intestinal microbiota dysbiosis by changing the proportions of some intestinal microbial phylotypes. In addition, correlation network-based analysis indicated that the key intestinal microbial phylotypes were closely related to biochemical parameters associated with MetS under GLP-Cr intervention. Liver metabolomics analysis suggested that GLP-Cr intervention significantly regulated the levels of some biomarkers involved in alpha-linolenic acid metabolism, fatty acid biosynthesis, steroid hormone biosynthesis, glycerophospholipid metabolism, glycerolipid metabolism, steroid hormone biosynthesis, primary bile acid biosynthesis, and so on. Moreover, GLP-Cr intervention regulated liver mRNA levels of key genes associated with glucose and lipid metabolism. The mRNA level of glucose transporter type 4 ( Glut4 ) was markedly increased by GLP-Cr intervention, and the mRNA levels of phosphoenolpyruvate carboxykinase ( Pepck ) and glucose-6-phosphatase ( G6Pase ) in the liver were significantly decreased. Meanwhile, GLP-Cr intervention significantly decreased hepatic mRNA levels of cluster of differentiation 36 ( Cd36 ), acetyl-CoA carboxylase 1 ( Acc1 ) and sterol regulatory element binding protein-1c ( Srebp-1c ), indicating that GLP-Cr intervention inhibited the excessive accumulation of free fatty acids in the liver. These findings suggest that the prevention of hyperglycemia and dyslipidemia by GLP-Cr may be closely related to the regulation of gut microbial composition and hepatic metabolic pathways, thus GLP-Cr can be serving as a functional component in the prevention of MetS.

Chromium (d-Phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities

Chromium Alleviates Glucose Intolerance, Insulin Resistance, and Hepatic Er Stress in Obese Mice

Chromium (D-Phenylalanine)3 Supplementation Alters Glucose Disposal, Insulin Signaling, and Glucose Transporter-4 Membrane Translocation in Insulin-Resistant Mice.

Insulin-Sensitizing and Cholesterol-Lowering Effects of Chromium (D-Phenylalanine)(3)

Chromium(D-Phenylalanine)(3) Improves Obesity-Induced Cardiac Contractile Defect in Ob/Ob Mice

Combined Chromium and Magnesium Decreases Insulin Resistance More Effectively Than Either Alone.

A Newly Synthetic Chromium Complex – Chromium(phenylalanine)3 Improves Insulin Responsiveness and Reduces Whole Body Glucose Tolerance

A Newly Synthetic Chromium Complex—chromium (D-Phenylalanine)3 Activates AMP-activated Protein Kinase and Stimulates Glucose Transport

Chromium-insulin Reduces Insulin Clearance and Enhances Insulin Signaling by Suppressing Hepatic Insulin-Degrading Enzyme and Proteasome Protein Expression in KKAy Mice

Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats.

Molecular mechanisms of chromium in alleviating insulin resistance.

Characterization of the Metabolic and Physiologic Response to Chromium Supplementation in Subjects with Type 2 Diabetes Mellitus

Chromium Alters Lipopolysaccharide-Induced Inflammatory Responses Both in Vivo and in Vitro.

Potential Ameliorative Effects of Chromium Supplementation on Glucose Metabolism, Obesity, and Genomic Stability in Prediabetic Rat Model

Organic chromium derived from the chelation of Ganoderma lucidum polysaccharide and chromium (III) alleviates metabolic syndromes and intestinal microbiota dysbiosis induced by high-fat and high-fructose diet

Chromium Improves Glucose Uptake and Metabolism Through Upregulating the Mrna Levels of Ir, Glut4, Gs, and Ucp3 in Skeletal Muscle Cells

Effect of chromium picolinate on insulin sensitivity in vivo

Chromium supplement inhibits skeletal muscle atrophy in hindlimb-suspended mice.

Chromium in Human Nutrition: A Review

Phenotype of Subjects with Type 2 Diabetes Mellitus May Determine Clinical Response to Chromium Supplementation

Oral Chromium Picolinate Improves Carbohydrate and Lipid Metabolism and Enhances Skeletal Muscle Glut-4 Translocation in Obese, Hyperinsulinemic (JCR-LA Corpulent) Rats.